Objectives: To propose our clinical classification of malignant ethmoid tumors and to compare it with the last American Joint Committee on Cancer (AJCC)-Union Internationale Contre le Cancer (UICC) classification, published in 1997. Design: Retrospective review. Setting: Tertiary cancer facility. Patients: We evaluated 123 consecutive patients undergoing craniofacial resection for malignant ethmoid tumors involving the anterior skull base. The mean follow-up was 60 months. Fifty-nine patients (48%) presented with recurrent disease after prior therapy. We classified them with a new classification system (Istituto Nazionale per lo Studio e la Cura dei Tumori) based on the most commonly accepted unfavorable prognostic factors (involvement of dura mater; intradural extension; involvement of the orbit and, in particular, of its apex; invasion of maxillary, frontal, and/or sphenoid sinuses; and invasion of the infratemporal fossa and skin. We also classified patients with the AJCC classification published in 1997. Main Outcome Measures: Disease-free status and overall survival rate. To study a possible association with tumor stage, the Cox regression model was adopted. Results: According to our classification, patient distribution by tumor type was T2, n = 46; T3, n = 29; and T4, n = 48 (no T1 tumors were present in the series). For previously untreated patients, 5-year disease-free survival estimates were T2, 57%; T3, 50%; and T4, 13%. For relapses, corresponding figures were T2, 31%; T3, 23%; and T4; 1%. The prognostic difference among stages was statistically significant (P < .001). Similar results were obtained for overall survival. In contrast, patient distribution among different AJCC stages was less balanced, and we failed to detect a significant association with the clinical outcome using this classification. Conclusion: We propose the use of our staging system by all those specialists in the field willing to validate the classification and possibly apply it for clinical and investigational purposes.

A new classification for malignant tumors involving the anterior skull base / G. Cantù, C.L. Solero, L. Mariani, F. Mattavelli, N. Pizzi, L. Licitra. - In: ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY. - ISSN 0886-4470. - 125:11(1999 Nov), pp. 1252-1257.

A new classification for malignant tumors involving the anterior skull base

L. Licitra
1999

Abstract

Objectives: To propose our clinical classification of malignant ethmoid tumors and to compare it with the last American Joint Committee on Cancer (AJCC)-Union Internationale Contre le Cancer (UICC) classification, published in 1997. Design: Retrospective review. Setting: Tertiary cancer facility. Patients: We evaluated 123 consecutive patients undergoing craniofacial resection for malignant ethmoid tumors involving the anterior skull base. The mean follow-up was 60 months. Fifty-nine patients (48%) presented with recurrent disease after prior therapy. We classified them with a new classification system (Istituto Nazionale per lo Studio e la Cura dei Tumori) based on the most commonly accepted unfavorable prognostic factors (involvement of dura mater; intradural extension; involvement of the orbit and, in particular, of its apex; invasion of maxillary, frontal, and/or sphenoid sinuses; and invasion of the infratemporal fossa and skin. We also classified patients with the AJCC classification published in 1997. Main Outcome Measures: Disease-free status and overall survival rate. To study a possible association with tumor stage, the Cox regression model was adopted. Results: According to our classification, patient distribution by tumor type was T2, n = 46; T3, n = 29; and T4, n = 48 (no T1 tumors were present in the series). For previously untreated patients, 5-year disease-free survival estimates were T2, 57%; T3, 50%; and T4, 13%. For relapses, corresponding figures were T2, 31%; T3, 23%; and T4; 1%. The prognostic difference among stages was statistically significant (P < .001). Similar results were obtained for overall survival. In contrast, patient distribution among different AJCC stages was less balanced, and we failed to detect a significant association with the clinical outcome using this classification. Conclusion: We propose the use of our staging system by all those specialists in the field willing to validate the classification and possibly apply it for clinical and investigational purposes.
Olfactory neuroblastoma; esthesioneuroblastoma; sinuses; cancer
Settore MED/06 - Oncologia Medica
nov-1999
Article (author)
File in questo prodotto:
File Dimensione Formato  
10555698 PMID.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 278.19 kB
Formato Adobe PDF
278.19 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/579705
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 32
social impact